Ponta Wealth Partners LLC Invests $504,000 in Gilead Sciences, Inc. $GILD

Ponta Wealth Partners LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,103 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

Several other large investors have also bought and sold shares of GILD. Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the 4th quarter worth $28,000. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Financial Consulate Inc. boosted its position in shares of Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. grew its stake in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares during the period. Finally, BOCHK Asset Management Ltd acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $31,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly outlook: Analysts’ previews expect steady Q1 2026 growth and the company has given FY26 EPS guidance consistent with continued revenue momentum, supporting the bullish case for near‑term earnings stability. Gilead Sciences Q1 2026 Earnings Preview: Steady growth ahead?
• Positive Sentiment: Governance cleared: Shareholders backed the board and executive pay plans at the 2026 meeting, reducing near‑term proxy risk and governance uncertainty for investors. Gilead Shareholders Back Board, Pay Plans at 2026 Meeting
• Positive Sentiment: Pipeline expansion via collaboration: Galapagos (Lakefront) announced a collaboration agreement with Gilead to advance a T‑cell engager, expected to close in Q2—this adds potential early‑stage oncology upside to Gilead’s R&D footprint. Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Yeztugo adoption is rising: Use of Gilead’s twice‑yearly HIV prevention shot has climbed since launch, which supports longer‑term PrEP revenue potential, though uptake remains variable. Focus: Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Claims on EPS impact: An advocacy group (AHF) published that Gilead’s EPS could surge due to state AIDS‑drug program disruptions; this could lift sentiment if confirmed by results but is disputed and should be weighed against company filings. Gilead’s Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF
• Neutral Sentiment: Analyst commentary: Roundups of healthcare analyst takes mention Gilead alongside peers but add little new near‑term catalyst; useful for tone but not material changes to consensus. Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD), AC Immune SA (ACIU) and Gilead Sciences (GILD)
• Negative Sentiment: Partner program shift: Arcus halted a Phase 3 lung trial and Gilead narrowed option rights on their collaboration, reducing future optionality on that program and signaling Gilead may be reprioritizing certain oncology bets—a potential long‑term negative to pipeline breadth. Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. This represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the chief financial officer directly owned 176,191 shares of the company’s stock, valued at $24,835,883.36. This represents a 1.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 63,000 shares of company stock valued at $9,238,250. 0.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GILD. Truist Financial increased their target price on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft increased their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Cantor Fitzgerald reduced their price objective on shares of Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, April 10th. Finally, Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $157.35.

Gilead Sciences Stock Up 2.1%

NASDAQ:GILD opened at $136.30 on Thursday. Gilead Sciences, Inc. has a 1 year low of $95.29 and a 1 year high of $157.29. The stock has a 50-day moving average price of $139.87 and a two-hundred day moving average price of $132.79. The stock has a market cap of $169.18 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 1.77 and a beta of 0.31. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the firm posted $1.90 earnings per share. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.